Heron Therapeutics (HRTX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Heron Therapeutics (HRTX)
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Key Insights
Critical company metrics and information
Share Price
$1.77Market Cap
$269.21 MillionTotal Outstanding Shares
152.10 Million SharesTotal Employees
126Dividend
No dividendIPO Date
August 27, 1987SIC Description
Pharmaceutical PreparationsHomepage
https://www.herontx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-1.54 Million |
Net Cash Flow | $-9.12 Million |
Net Cash Flow From Operating Activities, Continuing | $-8.29 Million |
Net Cash Flow From Investing Activities | $-1.54 Million |
Net Cash Flow From Operating Activities | $-8.29 Million |
Net Cash Flow From Financing Activities, Continuing | $716,000.00 |
Net Cash Flow, Continuing | $-9.12 Million |
Net Cash Flow From Financing Activities | $716,000.00 |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Cost Of Revenue | $38.30 Million |
Revenues | $137.74 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-27.97 Million |
Gross Profit | $99.43 Million |
Costs And Expenses | $125.35 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Basic Earnings Per Share | $-0.16 |
Other Operating Expenses | $87.28 Million |
Net Income/Loss | $-27.97 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Benefits Costs and Expenses | $125.35 Million |
Operating Income/Loss | $-25.92 Million |
Diluted Earnings Per Share | $-0.16 |
Net Income/Loss Attributable To Parent | $-27.97 Million |
Diluted Average Shares | $156.60 Million |
Income/Loss From Continuing Operations Before Tax | $12.38 Million |
Research and Development | $38.07 Million |
Income/Loss From Continuing Operations After Tax | $-27.97 Million |
Basic Average Shares | $156.60 Million |
Operating Expenses | $125.35 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities | $260.78 Million |
Other Non-current Assets | $10.18 Million |
Other Current Liabilities | $66.83 Million |
Noncurrent Assets | $25.59 Million |
Equity Attributable To Parent | $-40.01 Million |
Inventory | $45.95 Million |
Equity | $-40.01 Million |
Current Liabilities | $85.54 Million |
Liabilities And Equity | $220.78 Million |
Fixed Assets | $15.41 Million |
Noncurrent Liabilities | $175.24 Million |
Current Assets | $195.19 Million |
Assets | $220.78 Million |
Accounts Payable | $10.19 Million |
Cash | $70.90 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Other Current Assets | $78.34 Million |
Wages | $8.53 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.